Detalhe da pesquisa
1.
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric Cancer
; 27(3): 558-570, 2024 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308771
2.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet Oncol
; 23(1): 65-76, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871550
3.
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Lancet
; 396(10245): 186-197, 2020 07 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32682484
4.
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood
; 133(18): 1953-1963, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819926
5.
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncol
; 19(7): 953-964, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866475
6.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(10): 1327-1337, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28843768
7.
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
Br J Haematol
; 194(4): 784-788, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046887
8.
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma.
Leuk Lymphoma
; 62(12): 3002-3010, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180331
9.
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
Blood Cancer J
; 10(3): 35, 2020 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32152297
10.
Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.
Cancer Med
; 9(9): 2989-2996, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32108443
11.
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study).
Leukemia
; 33(12): 2934-2946, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092895
12.
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Int J Hematol
; 110(4): 466-473, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31388932